| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
CAMBRIDGE, U.K.—Horizon Discovery Group plc announced late last year the addition of a predesigned synthetic single guide RNA (sgRNA) option to its product range. The sgRNAs, available individually or as library collections, expand the company’s Edit-R gene engineering platform which provides a convenient and accessible approach to successful CRISPR gene editing.
Using synthetic sgRNAs enables researchers to achieve reliable gene knockouts in even complex, difficult-to-edit cell types and experimental models, the company says. The synthetic sgRNAs have been designed using Horizon’s proprietary algorithm to maximize the likelihood of functionally knocking out genes of interest while minimizing off-target effects.
 
These predesigned synthetic sgRNAs, when paired with Cas9 mRNA or Cas9 protein, reportedly allow researchers to perform DNA-free gene editing in a new one-part format thereby streamlining their gene editing workflows, without the potential for nuclease or guide integration into the cell’s genome. They can also be paired with expressed formats such as Cas9 integrated cell lines, which is ideal for high-throughput library screening.
 
The company will continue to provide its CRISPR design tool, where customers can design custom guide RNA to edit a specific region within a DNA transcript or input their own guide RNA target sequence to generate ready-to-use sgRNA.
 
“Previously, Horizon had only offered synthetic sgRNAs through the CRISPR Design tool. Providing predesigned synthetic sgRNAs guarantees editing the gene of interest, and gives researchers a more convenient option for gene knockout experiments,” said Ryan Donnelly, product manager at Horizon Discovery. “For those that require site-specific editing, are working in unique organisms, or use alternative editing nucleases; our CRISPR design tool is still available.”

Related Topics

Published In

Volume 16 - Issue 1 | January 2020

January 2020

January 2020 Issue

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue